Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
| Autor: | Surial, Bernard, Cavassini, Matthias, Calmy, Alexandra, Fehr, Jan, Stöckle, Marcel, Bernasconi, Enos, Roth, Bianca, Fux, Christoph A, Kovari, Helen, Furrer, Hansjakob, Rauch, Andri, Wandeler, Gilles, Swiss HIV Cohort Study |
|---|---|
| Přispěvatelé: | Swiss HIV Cohort Study, Anagnostopoulos, A., Battegay, M., Bernasconi, E., Böni, J., Braun, D.L., Bucher, H.C., Calmy, A., Cavassini, M., Ciuffi, A., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Fux, C.A., Günthard, H.F., Haerry, D., Hasse, B., Hirsch, H.H., Hoffmann, M., Hösli, I., Huber, M., Kahlert, C.R., Kaiser, L., Keiser, O., Klimkait, T., Kouyos, R.D., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Marzolini, C., Metzner, K.J., Müller, N., Nicca, D., Paioni, P., Pantaleo, G., Perreau, M., Rauch, A., Rudin, C., Scherrer, A.U., Schmid, P., Speck, R., Stöckle, M., Tarr, P., Trkola, A., Vernazza, P., Wandeler, G., Weber, R., Yerly, S., University of Zurich, Wandeler, Gilles |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine HIV Infections Logistic regression Cohort Studies 10234 Clinic for Infectious Diseases 0302 clinical medicine Risk Factors Drug Interactions Tenofovir alafenamide 030212 general & internal medicine Alanine Reverse-transcriptase inhibitor Switch Middle Aged Antiretroviral therapy 3. Good health Infectious Diseases Cohort Female Adenine/analogs & derivatives Adenine/therapeutic use Adult Anti-HIV Agents/therapeutic use CD4 Lymphocyte Count HIV Infections/complications HIV Infections/drug therapy Hepatitis C Chronic/complications Hepatitis C Chronic/pathology Humans Switzerland Tenofovir/adverse effects Tenofovir/therapeutic use Tenofovir disoproxil fumarate Toxicity Research Article medicine.drug Cohort study medicine.medical_specialty Anti-HIV Agents 610 Medicine & health lcsh:Infectious and parasitic diseases 03 medical and health sciences 360 Social problems & social services Internal medicine medicine lcsh:RC109-216 Tenofovir business.industry Adenine 10060 Epidemiology Biostatistics and Prevention Institute (EBPI) 2725 Infectious Diseases Odds ratio Hepatitis C Chronic 030112 virology Confidence interval Regimen 10036 Medical Clinic business |
| Zdroj: | BMC infectious diseases, vol. 19, no. 1, pp. 834 BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-9 (2019) BMC Infectious Diseases Surial, Bernard; Cavassini, Matthias; Calmy, Alexandra; Fehr, Jan; Stöckle, Marcel; Bernasconi, Enos; Roth, Bianca; Fux, Christoph A; Kovari, Helen; Furrer, Hansjakob; Rauch, Andri; Wandeler, Gilles (2019). Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. BMC infectious diseases, 19(1), p. 834. BioMed Central 10.1186/s12879-019-4454-9 |
| DOI: | 10.1186/s12879-019-4454-9 |
| Popis: | BackgroundTenofovir alafenamide (TAF)-containing combinations were introduced in Switzerland after October 2016 and are recommended over tenofovir disoproxil fumarate (TDF) in patients with osteoporosis or impaired renal function.MethodsWe included all participants of the Swiss HIV Cohort Study on TDF-containing antiretroviral therapy with follow-up visits after January 2016. We determined the proportion of switches from TDF to TAF overall, and among patients with risk factors for TDF toxicity, including osteoporosis, impaired renal function or marked proteinuria. We used multivariable logistic regression to explore predictors of switching from TDF to TAF.ResultsWe included 5′012 patients, of whom 652 (13.0%) had risk factors for TDF toxicity. A switch from TDF to TAF was undertaken in 2′796 (55.8%) individuals overall, and in 465 (71.3%) with risk factors. Predictors of switching to TAF were male sex (adjusted odds ratio 1.27, 95% confidence interval 1.07–1.50), age > 50 years (1.43, 1.23–1.66) and the presence of risk factors for TDF toxicity (2.21, 1.77–2.75). In contrast, patients with a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based single-pill regimen (0.11, 0.09–0.13), those treated in non-tertiary care centers (0.56, 0.46–0.70), as well as those with CD4 cell counts below 500/μL (0.77, 0.66–0.90) and with chronic hepatitis C infection (0.66, 0.54–0.80) were most likely to stay on TDF.ConclusionsOver 50% of patients on TDF-containing therapy, including the majority of patients at risk for TDF toxicity, were switched to TAF within two years of its introduction in Switzerland. Individuals on NNRTI-based single-pill regimens were most likely to remain on TDF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|